Gepotidacin is a novel antibiotic currently under development. The objective of the project is to explore a potential new option for the treatment of pharyngeal Neisseria gonorrhoeae infections or prostatitis caused by Escherichia coli by demonstrating adequate penetration of a novel antibiotic in tonsillar and prostate tissues.
This AB-DIRECT project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 853976. The JU receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.
By continuing your navigation, you accept the deposit of third-party cookies intended to offer you videos, sharing buttons, content uploads from social platforms. Learn more
Measure of audience
This site uses audience measurement and analysis cookies, such as Google Analytics, in order to evaluate and improve our website.
This site uses third-party components, such as NotAllowedScript6170143081d70ReCAPTCHA, Google NotAllowedScript6170143081c7eMaps, which may deposit cookies on your machine. If you decide to block a component, the content will not be displayed